# Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

> **NCT04762979** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Marina N Sharifi** · enrollment: 44 (estimated)

## Conditions studied

- Hormone Receptor Positive Breast Carcinoma
- HER2-negative Breast Cancer
- PIK3CA Mutant Metastatic Breast Cancer

## Interventions

- **DRUG:** Alpelisib
- **DRUG:** Fulvestrant
- **DRUG:** Aromatase inhibitor

## Key facts

- **NCT ID:** NCT04762979
- **Lead sponsor:** Marina N Sharifi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-12
- **Primary completion:** 2025-10-23
- **Final completion:** 2026-05
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762979, "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04762979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*